Projects / Programmes
Genotoxic and late effect of treatment on somatic cells of patients with testicular tumor
| Code |
Science |
Field |
Subfield |
| 3.04.00 |
Medical sciences |
Oncology |
|
| Code |
Science |
Field |
| B520 |
Biomedical sciences |
General pathology, pathological anatomy |
testicular tumour, structural chromosomal aberrations, radiotherapy, chemotherapy
Researchers (7)
Organisations (1)
| no. |
Code |
Research organisation |
City |
Registration number |
No. of publicationsNo. of publications |
| 1. |
0302 |
Institute of Oncology Ljubljana |
Ljubljana |
5055733000 |
15,455 |
Abstract
We observed that, before treatment, the amount of chromosomal aberration in the patients with testicular tumor and in the control group is the same. However, after applying different treatment modalities, we noticed that the mitotic activity of lymphocytes, genome as well the number and type of chromosomal aberrations were changed. Six months after the completed treatment, the mitotic activity of lymphocytes was practically restored to normal, whereas the values of chromosomal aberrations were different, depending on the treatment modality applied, yet still high in comparison to the initial ones. We resolved that the period of six - months is too short to allow genome normalization. From the cyto-mutagenic point of view, the irradiation had stronger effect on the genome that the treatment with cytostatics, which was mainly due to highly increased values of unstable chromosomal aberration. In irraddiated patients, there werw at least two reasons for a faster - normalization of cytogenetic condition; (1) only a part of the organ was exposed to genotoxic agents and,
(2) after irradiation, a considerably high number of unstable chromosome changes occurred that are incompatible with the cell survival. The questions that arise from the above findings are as follows: What will be the genome picture in the patients five years after the completed treatment. Wath percentage of local recurrences is anticipated after different treatment modalities with taking into account the stage of the disease before treatment. Is there a correlation between the number of chromosome changes and recurrence or between a new primary and genome picture. What is the reproduction function of the patients with testicular tumor. We presume that the repeated examination of the genome, clinical examination of the patients, diagnostic imaging, biochemistry and blood count and tumor marker may provide the answers to the above questions.
